Differential expression of Ia molecules by human monocytes.

T A Gonwa, J D Stobo

Research Article

Human immune response genes can be divided into three distinct loci, each of which codes for three distinct families of Ia molecules: HLA-SB, HLA-DC, and HLA-DR. The tissue distribution and function of only one of these Ia molecules, HLA-DR, has been thoroughly studied. Using monoclonal antibodies, we examined the display of HLA-DR and HLA-DC molecules by adherent, human peripheral blood monocytes. The results of these studies demonstrate that although all human peripheral blood monocytes display easily detectable HLA-DR molecules, only 50% display easily detectable HLA-DC molecules. Separation of peripheral blood monocytes into HLA-DC+ and HLA-DC- cells demonstrates that each population displays an equivalent density of HLA-DR molecules. Therefore, on the basis of differences in their display of these two Ia molecules, adherent peripheral blood monocytes can be divided into two broad populations: HLA-DR+, HLA-DC+, and HLA-DR+, HLA-DC-. Despite the dis-coordinate display of these Ia antigens, the expression of both HLA-DR and HLA-DC can be regulated by a common signal, gamma interferon (IFN-gamma). Incubation of monocytes for 96 h in autologous serum leads to a marked decrease in the expression of both HLA-DR and HLA-DC. Addition of recombinant IFN-gamma to the cultures leads to reexpression of both HLA-DR and HLA-DC to levels comparable to those seen in fresh monocytes. In addition, although IFN-gamma does not modulate all monocyte surface markers, it […]

Find the latest version:

https://jci.me/111503/pdf

Differential Expression of Ia Molecules by Human Monocytes

Thomas A. Gonwa and John D. Stobo
The Howard Hughes Medical Institute and the Department of Medicine, University of California, San Francisco, California 94143

Abstract. Human immune response genes can be divided into three distinct loci, each of which codes for three distinct families of Ia molecules: HLA-SB, HLA-DC, and HLA-DR. The tissue distribution and function of only one of these Ia molecules, HLA-DR, has been thoroughly studied. Using monoclonal antibodies, we examined the display of HLA-DR and HLA-DC molecules by adherent, human peripheral blood monocytes. The results of these studies demonstrate that although all human peripheral blood monocytes display easily detectable HLA-DR molecules, only 50% display easily detectable HLA-DC molecules. Separation of peripheral blood monocytes into HLA-DC$^+$ and HLA-DC$^-$ cells demonstrates that each population displays an equivalent density of HLA-DR molecules. Therefore, on the basis of differences in their display of these two Ia molecules, adherent peripheral blood monocytes can be divided into two broad populations: HLA-DR$^+$, HLA-DC$^+$, and HLA-DR$^+$, HLA-DC$^-$. Despite the discoordinate display of these Ia antigens, the expression of both HLA-DR and HLA-DC can be regulated by a common signal, gamma interferon (IFN-γ). Incubation of monocytes for 96 h in autologous serum leads to a marked decrease in the expression of both HLA-DR and HLA-DC. Addition of recombinant IFN-γ to the cultures leads to reexpression of both HLA-DR and HLA-DC to levels comparable to those seen in fresh monocytes. In addition, although IFN-γ does not modulate all monocyte surface markers, it can be demonstrated to modulate expression of one marker, MAC 120, in a manner similar to that observed for Ia antigens. These studies demonstrate that among human peripheral blood monocytes, the distribution of the Ia molecule, HLA-DC, is not coordinate with that of HLA-DR, although both respond to the same regulatory signal.

Introduction

Expression of Ia molecules by accessory cells, such as peripheral blood adherent monocytes (Mϕ),[1] is necessary for their ability to initiate and regulate immune reactivity (1–4). In mice, two Ia molecules, I-E and I-A, encoded for by genes within the I region have been described. In humans, three groups of molecules whose general structure resembles murine Ia molecules have been delineated, HLA-DC (DS), HLA-DR, and HLA-SB (5–13). Published studies indicate that two of these, HLA-SB and HLA-DR, have a tissue distribution similar to that described for murine Ia molecules. Both HLA-SB and HLA-DR are displayed by B cells and Mϕ (4, 11–13). In contrast to these studies, little is known about the tissue distribution of HLA-DC. We have previously provided indirect evidence indicating that although HLA-DC is present on the surface of Mϕ, only ~50% of peripheral blood Mϕ are HLA-DC$^+$ (14). This suggests that there is heterogeneity among peripheral Mϕ in regards to Ia expression. Furthermore, other studies from our laboratory have demonstrated that the human monocytoid cell line U-937 can be induced to express HLA-DR. This expression represents a pretranslational event induced by human recombinant gamma interferon (IFN-γ, 15). In those experiments, expression of HLA-DC was never seen with the expression of HLA-DR. This suggests that not only may there be discoordinate expression of HLA-DR and HLA-DC in normal Mϕ but that the regulatory signals governing expression of these Ia antigens may be different. Studies in the murine system have demonstrated that both I-A and I-E can be induced by a soluble factor released by activated T cells (16–21). One of these factors has been demonstrated to be

1. *Abbreviations used in this paper:* CM, culture media; IFN-γ, human recombinant gamma interferon; Mϕ, peripheral blood adherent monocyte; PBMC, peripheral blood mononuclear cells; MCF, mean channel fluorescence.

IFN-γ (22–23). In the human, however, only modulation of HLA-DR expression by supernatants of activated T cells and IFN-γ has been studied (24–27).

In the present study, we investigated the heterogeneity of Mφ Ia expression directly by using a monoclonal antibody specific for HLA-DR, two monoclonal antibodies specific for HLA-DC molecules, and a rabbit heterosera specific for HLA-DC molecules. We demonstrate that there is discoordinate expression of HLA-DR and HLA-DC among normal human peripheral monocytes. However, despite discoordinate expression, both Ia molecules appear to be under the regulatory control of the lymphokine IFN-γ. We also demonstrate that IFN-γ can modulate the expression of another Mφ marker, MAC 120.

Methods

Antibodies. CA 206 is an IgG2b mouse monoclonal antibody that is specific for nonpolymorphic determinants of HLA-DR molecules (14). Rb03 is a rabbit serum that is directed against Ia molecules whose amino acid sequence is distinct from HLA-DR and homologous to murine I-A (5, 6, 14). These molecules have been termed HLA-DS or DC (6, 7) and for convenience will be called HLA-DC in this paper. Leu 10 is an IgG1 mouse monoclonal antibody, which was a gift from the Becton-Dickinson Monoclonal Center, Inc., Mountain View, CA. Leu 10 was derived from the fusion of mouse NS-1 cells with spleen cells of BALB/c mice immunized with tonsillar B cells (Chen, Y. X., F. Brodsky, R. L. Evans, and N. L. Warner; manuscript in preparation). It reacts with B cells of all DR specificities except for homozygous DR 3 and DR 7 cells and the molecule it depicts is distinct from HLA-DR. On the basis of competitive binding and sequential immunoprecipitation, Leu 10 appears to react with HLA-DC molecules (28). Studies from our laboratory indicate that Leu 10 immunoprecipitates an Ia molecule distinct from HLA-DR and electrophoretically identical to that precipitated by a known anti HLA-DC sera, Rb03 (Gonwa, T., and J. Stobo; unpublished observations). Genox 3.53 is a mouse monoclonal antibody known to be directed against an HLA-DC molecule associated with HLA-DR 1, 2, and 6 (8). This molecule has an amino acid sequence distinct from HLA-DR, identical to that precipitated by Rb03, and homologous to murine I-A (7). It was the gift of Dr. F. Brodsky (Becton-Dickinson & Co., Mountain View, CA). The mouse IgM monoclonal antibody MAC 120 identifies a 120,000-D molecule displayed on the surface of a subset of Mφ that are important in antigen presentation (29). The expression of this Mφ marker has been previously demonstrated to correlate with HLA-DC (DS) expression (14). This antibody is also known as Leu M2 (Becton-Dickinson & Co.) and was used as supplied by the company. Leu M3 is a mouse IgG monoclonal antibody that reacts with mature monocytes (30); it was the gift of Becton-Dickinson & Co. For controls, the IgG myeloma protein MOPC 195 or the IgM myeloma protein MOPC 104E (Bionetics Laboratory Products, Kensington, MD) was used.

Fluorescent analysis was performed by using an indirect immunofluorescent technique. Cells to be analyzed were incubated with the first antibody under saturating conditions for 30 min at 4°C, washed, and incubated with saturating amounts of either an F(ab')₂ fluoresceinated goat anti-mouse antibody or an F(ab')₂ fluoresceinated goat anti-rabbit Ig antibody. Controls consisted of cells incubated with either an isotype matched myeloma protein or normal rabbit serum in the first

step followed by the fluoresceinated second antibody (Cappel Laboratories, West Chester, PA) for 30 min at 4°C. Cells were then washed twice over 5% bovine serum albumin, resuspended in phosphate-buffered saline, and analyzed by flow cytometry using log amplification on an FACS IV (Becton-Dickinson & Co.). This technique has been previously described (14).

Isolation and culture of peripheral blood monocytes. Peripheral blood mononuclear cells (PBMC) were obtained from normal donors and adhered on plastic petri dishes as previously described (29). Nonadherent cells were removed by vigorous washing. Adherent cells were removed with lidocaine as described (29) and these constituted the adherent peripheral blood monocyte (Mφ) population (>95% esterase positive). In the culture experiments described, Mφ were suspended in RPMI-1640 media with 10% heat-inactivated autologous serum and cultured on bacteriological petri dishes (Falcon Labware, Oxnard, CA) at 37°C in a humidified 95% O₂:5% CO₂ atmosphere. For some experiments, Mφ were incubated in the presence of conditioned media (CM) derived from activated T cells as a source of Ia inducing material. This was prepared as previously described (15). Briefly, PBMC were incubated at a concentration of 0.5 × 10⁶ cells/ml in RPMI 1640 supplemented with 10% fetal calf serum and concanavalin A (15 μg/ml, ICN Nutritional Biochemicals, Cleveland, OH) for 48 h at 37°C. The cells were removed by centrifugation, the concanavalin A was removed by absorption of the CM with sepharose 4B (Pharmacia, Uppsala, Sweden), and the CM was stored at −70°C until use. For some experiments, Mφ were incubated in the presence of human recombinant gamma interferon isolated from *Escherichia coli* (IFN-γ, the gift of Genentech Inc., South San Francisco, CA).

Results

Adherent Mφ are one cell type capable of presenting antigen to T cells (14, 29, 31, 32). This requires the display of appropriate Ia molecules. We and others have previously demonstrated that all Mφ display easily detectable HLA-DR molecules (14, 31, 33, 34). Previous studies from this laboratory provided indirect evidence suggesting that only ~50% of peripheral blood Mφ also display easily detectable HLA-DC molecules (14). To directly analyze the display of HLA-DC by Mφ, saturating amounts of Leu 10 were used to stain peripheral blood Mφ from normal donors. A typical experiment is depicted in Fig. 1. All Mφ display easily detectable HLA-DR molecules. However, only ~50% display reactivity with Leu 10, which is greater than the reactivity noted with the control myeloma protein (MOPC 195). Therefore, only 50% of Mφ are HLA-DC positive when compared with control. Similar results were obtained by using two other known anti-DC reagents, Rb03 and Genox 3.53, and the peripheral blood Mφ from individuals of several different HLA-DR phenotypes. (Genox only stains Mφ from individuals who are HLA-DR 1, 2, or 6.)

In no instance was the frequency of cells expressing HLA-DC molecules noted to be greater than the frequency of cells expressing HLA-DR molecules. One explanation for this apparent discrepancy of Ia antigen expression could be the state of maturation of the Mφ. Incubation of murine Mφ in supernatants from activated T cells (CM) or IFN-γ increases

ADHERENT PERIPHERAL BLOOD MONOCYTES

Figure 1. Analysis of HLA-DR and HLA-DC expression by adherent peripheral blood Mϕ. Mϕ were obtained as detailed in Methods and analyzed for reactivity with the control myeloma protein MOPC 195 (control), CA 206 (anti HLA-DR), or with Leu 10 (anti HLA-DC). The cells were initially reacted with saturating amounts of the first antibody, washed, and incubated with saturating amounts of a fluoresceinated F(ab')$_2$ goat anti-mouse Ig. The percentage of cells reacting with the antibodies greater than control is indicated in the parentheses. The results are representative of six experiments in separate individuals, performed with three different anti-HLA-DC reagents: Leu 10, Genox 3.53, and Rb03.

expression of Ia. Therefore, we incubated freshly isolated Mϕ in human CM for 24 h and then assayed the expression of HLA-DR and HLA-DC. After this incubation, although HLA-DR expression increased slightly, the number of HLA-DC$^+$ Mϕ remained the same (data not shown). The CM used in these experiments was active in that it could induce the expression of Ia molecules by a human monocytoid cell line. Therefore, although all Mϕ appear to be HLA-DR$^+$, only 50% display easily detectable HLA-DC molecules and this cannot be increased by soluble materials capable of enhancing Ia expression.

It could be argued that Mϕ defined as HLA-DC$^-$ actually display too few HLA-DC molecules to be detected by flow cytometry. This question was addressed in two sets of experiments. First, assuming coordinate expression of these Ia molecules, one might expect these HLA-DC$^-$ cells would also express a low density of HLA-DR. To examine this possibility, Mϕ were stained with Leu 10 and sterilely sorted into HLA-DC$^+$ and HLA-DC$^-$ populations by using an FACS IV. HLA-DC$^+$ included all cells staining greater than the MOPC control. HLA-DC$^-$ consisted of the remaining population. The HLA-DC$^+$ and HLA-DC$^-$ populations were then incubated overnight in autologous serum and reanalyzed for the expression of both HLA-DC and HLA-DR. Restaining the populations for expression of HLA-DC after an overnight incubation demonstrated that the HLA-DC$^-$ population remained HLA-DC$^-$ (no cells staining greater than control), while the HLA-DC$^+$ population remained HLA-DC$^+$ (all cells stained greater than control, data not shown). The two populations were analyzed for the expression of HLA-DR determinants by using the monoclonal anti-HLA-DR antibody, CA 206. As can be seen in Fig. 2, the frequency of HLA-DR positive cells as well as the density of HLA-DR per cell were identical in each population. Separating the HLA-DC$^+$ and HLA-DC$^-$ populations utilizing the anti-DC1 monoclonal antibody Genox 3.53 gave identical results.


Figure 2. Mϕ expression of HLA-DR does not correlate with the expression of HLA-DC. Mϕ were separated into HLA-DC$^+$ and HLA-DC$^-$ populations by sorting on an FACS. Both populations were incubated overnight in 10% autologous serum and then analyzed by flow cytometry for reactivity with the control myeloma protein MOPC 195 (control) or CA 206 (anti HLA-DR) as described in Fig. 3. This is representative of two experiments in HLA-DR disparate individuals.

Thus, HLA-DR expression by HLA-DC$^+$ and HLA-DC$^-$ Mϕ is equivalent. The expression of these Ia molecules is not coordinate.

Secondly, the number of HLA-DR and HLA-DC molecules present on the cell surface of Mϕ was quantitated in two individuals by using flow cytometry with log amplification (35–37). Fluorescent staining with MOPC 195 (control) gave a mean channel fluorescence (MCF) of 30 and 31. Fluorescent staining with CA 206 (anti HLA-DR) gave an MCF of 83 and 84, respectively. In these experiments, the calibration curve generated indicated that a log difference in fluorescence was 62 channels. Thus, the technique can measure up to a log difference in fluorescent intensity and because the experiments were performed under saturating conditions, this implies a log difference in molecules. In the same experiment, the MCF of the population of Mϕ that would be considered HLA-DC$^-$, i.e., staining no greater than control, was determined by using utilizing Leu 10 as the anti-HLA-DC reagent. These values were 38 and 39, respectively. Using the above mentioned calibration curve, this indicates that the average density of HLA-DC molecules in the HLA-DC$^-$ population was 20–25% of the density of HLA-DR molecules. The MCF of the HLA-DC$^+$ population determined with Leu 10 was 78 and 78, no different than staining with CA-206. The average number of HLA-DR molecules present on Mϕ is 120,000/cell (37). Thus, the HLA-DC$^-$ Mϕ may express on the average no more than 24,000–30,000 HLA-DC molecules. We have previously dem-

onstrated that these cells do not function as effectively in antigen presentation as the DR$^+$ DC$^+$ Mϕ (14).

To determine if the absence of HLA-DC expression among a subpopulation of Mϕ is a stable phenotype, we studied changes in expression of this molecule which might occur during culture. This has been demonstrated to mimic Mϕ maturation (38, 39). Mϕ were incubated in 10% autologous serum and at 24 and 96 h analyzed for HLA-DR and HLA-DC expression. As demonstrated in Fig. 3, at no time during culture was there an increase in HLA-DC expression and by 96 h, HLA-DC expression had almost entirely disappeared. At this time, the frequency of HLA-DR$^+$ Mϕ had also decreased.


Figure 3. Expression of HLA-DR and HLA-DC by cultured Mϕ. Peripheral blood Mϕ were cultured in autologous serum for the times indicated. They were then harvested and analyzed for their reactivity with Leu 10 (anti-HLA-DC), CA 206 (anti-HLA-DR), or the myeloma protein MOPC 195 (control) by using indirect immunofluorescence and flow cytometry as described in Fig. 3. This is representative of two experiments.

Therefore, the failure of 50% of the Mϕ to display HLA-DC molecules does not relate to a time dependent maturation event which can be mimicked by culture.

One explanation for the discoordinate expression of HLA-DR and HLA-DC by Mϕ could be that they are under separate regulatory control. To investigate this, we used cultured Mϕ as a source of Mϕ whose Ia expression could be increased. Mϕ were obtained from normal donors and placed in culture with autologous serum. At 7 d, fresh autologous serum with or without human recombinant IFN-γ (100 IU/ml) was added to the cultures. 48 h later, cells were harvested, washed, and analyzed for expression of HLA-DR and HLA-DC. At the same time, freshly prepared Mϕ from the same donor were assayed for expression of HLA-DR and HLA-DC. Results of a typical experiment are shown in Fig. 4. Cultured Mϕ lose expression of most of their HLA-DR and all of their HLA-DC. After incubation in IFN-γ, the expression of both Ia antigens is increased to the density present on fresh Mϕ. Similar results were obtained by using CM instead of IFN-γ. This suggests that the factor present in CM that induces HLA-DR and HLA-DC is IFN-γ. This finding was demonstrated by using Genox 3.53, Leu 10, and Rb03. Further experiments indicated that HLA-DR and HLA-DC could be induced with as little as 10 IU/ml of IFN-γ. However, 50–100 IU/ml was optimum with amounts >100 IU/ml inducing no greater increase in Ia antigen expression. Therefore, for most experiments 100 IU/ml of IFN-γ was used. Experiments performed with the monocyte cell lines U-937 and HL-60 have indicated that increase in Ia expression induced by IFN-γ can be detected as soon as 4 h after addition of IFN-γ (15, and footnote 2). Maximal expression was at 48 h. Thus, although Mϕ are discoordinate in their expression of HLA-DR and HLA-DC, both Ia antigens appear to be under the regulatory control of the same lymphokine, IFN-γ.

We next investigated changes in two other Mϕ markers induced by culture. Leu M3 is a mouse monoclonal antibody that reacts with mature monocytes (30). Leu M2 is the mouse monoclonal antibody MAC 120. This antibody reacts with a subset of peripheral monocytes that are important in antigen presentation. Expression of MAC 120 has been correlated with expression of HLA-DC (14). Mϕ were isolated from a normal donor and placed in culture with autologous serum. After 48 h, fresh medium with or without IFN-γ (10 IU/ml) was added to the cultures. This concentration of IFN-γ was used based on preliminary experiments that indicated that 10 IU/ml of IFN-γ was optimal for inducing monocyte markers in the monocyte line HL-60.[2] 48 h later, the cells were harvested and assayed for expression of Leu M3 and MAC 120. Freshly isolated Mϕ from the same donor were isolated and analyzed for Leu M3 and MAC 120. A typical experiment (representative of three done in different individuals) illustrates the results of

---

2. Gonwa, T. A., B. M. Peterlin, and J. D. Stobo. Unpublished observations.

Figure 4. IFN-γ modulates HLA-DR and HLA-DC expression in normal human monocytes. Freshly isolated Mφ (fresh), Mφ cultured for 7 d (cultured), and 7-d cultured Mφ incubated for an additional 48 h with 100 IU/ml of IFN-γ (cultured ± IFN-γ) from the same donor were analyzed for reactivity with the myeloma protein MOPC 195 (control), the monoclonal antibody CA 206 (anti HLA-DR), or the monoclonal antibody (Genox 3.53 (anti HLA-DC) by using indirect immunofluorescence under saturating conditions and flow cytometry with log amplification. The results presented are representative of three experiments performed with two different anti-HLA-DC reagents: Leu 10 and Genox 3.53.

this experiment (Fig. 5). Expression of Leu M3 does not change with culture, nor is its expression modulated by IFN-γ. Although it appears that the expression of Leu M3 has increased in the cultured Mφ, note that the staining with control antibody has also increased. This increase in autofluorescence is characteristic of cultured cells. The difference between staining with control and with Leu M3 in the two populations is not different. Thus, not all Mφ surface markers decrease during culture nor do they all appear to be under the regulatory influence of IFN-γ. In contrast, MAC 120 displays a pattern similar to that seen with Ia antigens. Culture of Mφ results in disappearance of MAC 120 expression. MAC 120 expression is lost as soon as 24 h after initiating culture. Exposure of the cultured Mφ to IFN-γ results in the re-expression of MAC 120. Thus, the expression of this Mφ marker, which has previously been correlated with expression of HLA-DC, also appears to be under regulatory control. The cell surface antigen with which MAC 120 reacts is shared by platelets (N. Warner, personal communication). Therefore, one concern is that the expression of MAC 120 by Mφ merely represents platelet satellitism. The above experiments demonstrate that MAC 120 is indeed expressed by Mφ as they were done with serum that had been centrifuged at 35,000 *g* for 10 min before use. This procedure removes all platelets and platelet membrane microparticles (40). The reexpression of MAC 120 induced by purified IFN-γ represents synthesis by Mφ and cannot be ascribed to absorption of platelets or platelet membrane microparticles onto the Mφ.

Discussion

The recent availability of molecular probes for genes in the human major histocompatability complex has advanced our knowledge concerning the organization and structure of immune response genes and their products. It is clear that there exist three distinct human immune response loci that code for

three families of Ia molecules, HLA-DC, HLA-DR, and HLA-SB. Furthermore, each of these loci may contain multiple copies of the genes coding for α- and β-chains (5–14, 41–44). Studies of the expression, tissue distribution, fine structure, and function of each family of human Ia molecules has been hampered by the paucity of reagents reacting with individual molecules. In this study, we use monoclonal antibodies to examine the tissue distribution of two Ia molecules. One of these antibodies, CA 206, reacts with molecules coded for by genes within the HLA-D locus: HLA-DR molecules (14, 32). The other antibodies, Leu 10, Genox 3.53, and Rb03 depict a molecule (HLA-DC) that has an amino acid sequence distinct from HLA-DR molecules and is encoded for by distinct genes (5–9, 28). The studies demonstrate that although all Mφ display classical HLA-DR, only approximately half display a substantial density of HLA-DC. These findings confirm our previous studies suggesting heterogeneity among peripheral Mφ in regards to their display of Ia molecules (14). In a previous report, we demonstrated that peripheral blood Mφ could be divided into two populations based on their display of a molecule depicted by the antibody MAC 120. MAC 120$^+$ Mφ displayed both HLA-DR and HLA-DC molecules. MAC 120$^-$ Mφ were in contrast HLA-DR$^+$ and HLA-DC$^-$. We have previously demonstrated functional differences between these two populations of Mφ (14).

It is not clear from these studies whether or not there are some Mφ that are truly HLA-DC$^-$. It is clear that some Mφ stain with anti-HLA-DC reagents no brighter than the control myeloma protein. This suggests that they are either HLA-DC negative or display very low density of HLA-DC molecules. As indicated in the results, the HLA-DC$^-$ Mφ could display 24,000–30,000 HLA-DC molecules on average compared with 100–120,000 HLA-DC molecules present on HLA-DC$^+$ Mφ. However, the data presented in Fig. 2, showing that HLA-DC$^+$ and HLA-DC$^-$ Mφ have comparable densities of HLA-DR molecules, support the concept that there need not be

*Figure 5.* IFN-γ modulates expression of Leu M2 (Mac-120) in normal monocytes. Freshly isolated Mφ (fresh), Mφ cultured for 4 d (cultured), or 4-d cultured Mφ incubated an additional 48 h with 10 IU/ml of IFN-γ were analyzed for reactivity with a myeloma control protein (control), the monoclonal antibody Leu M2, or the monoclonal antibody Leu M3 by using indirect immunofluorescence and flow cytometry with log amplification. The control for Leu M2 was MOPC 104E and the control for Leu M3 was MOPC 195. These gave equal staining of the cell populations and are represented by one line.

coordinate display of Ia molecules by Mφ. Similar discoordinance of expression has been demonstrated for murine Ia molecules. Three studies demonstrate that murine Mφ differ in their expression of I-A and I-E (45–47). Huber and Rosenwasser (48) have demonstrated that the sex-linked Ia determinant Ia.W39 was expressed on some but not all splenic Mφ (48). Furthermore, recent studies using human pre-B cell lines indicate that HLA-DR is expressed before the expression of HLA-DC (49). This suggests that the initial signals for expression of these Ia molecules may be different. Whether or not the differential expression of Ia molecules and the existence of Mφ

subsets are stable phenotypes is not clear. The studies outlined in Fig. 3 demonstrate that DC⁻ Mφ do not become DC⁺ after 4 d in culture. Moreover, it is possible to demonstrate that incubation of fresh normal Mφ in IFN-γ, a process potentially capable of increasing both HLA-DR and HLA-DC expression, does not result in an increase in the percentage of HLA-DC⁺ Mφ (data not shown). It should be noted that at 24 h, the density of HLA-DR on Mφ increased slightly when compared with fresh Mφ. This has been reported by others (33, 50). However, continuation of cultures ·beyond 24 h leads to a decrease in HLA-DR expression. This initial increase may represent residual soluble factors either secreted by contaminating lymphocytes or present in small amounts in human serum. The gradual decrease of Ia antigen expression may represent the depletion of these factors necessary for Ia antigen expression. These studies demonstrate that the expression of Ia antigens by Mφ is not a static event but requires constant regulatory signals that modulate expression.

Despite discoordinate expression of HLA-DR and HLA-DC among human Mφ, the data presented in Fig. 4 demonstrate that the display of both molecules can be regulated by the same signal, IFN-γ. The level of this control has been demonstrated to be pretranslational for expression of HLA-DR in the human monocyte cell line U-937 (15), the myelomonocytic cell line HL-60,[2] and in human B lymphoid and melanoma cell lines (51). Molecular mechanisms of IFN-γ control of HLA-DC expression are under study. Thus, similar to the murine system, IFN-γ appears to regulate all classes of Ia expression (22, 23).

Not all surface markers are under regulatory control by IFN-γ. The data presented in Fig. 5 demonstrate that culture or IFN-γ has no effect on the expression of the mature monocyte marker Leu M3. In contrast, the expression of MAC 120 (defined by Leu M2) can be enhanced by IFN-γ. This finding also demonstrates conclusively for the first time that Mφ express MAC 120 directly rather than stain with this antibody because of platelets adhered to their cell surface (platelet satellitism). Confirmation of this finding can be found in experiments that demonstrate that purified IFN-γ induce MAC 120 in previously negative HL-60 cells[2] and that the vitamin D metabolite 1,25-dihydroxy vitamin D₃ induces expression of MAC 120 in HL-60 cells (52, 53). Why this surface marker should be under regulatory control similar to Ia antigens is unknown. It is interesting that MAC 120 correlates with HLA-DC expression (14) and that it marks a functionally distinct subset of Mφ. Further studies of the relationship of this Mφ membrane protein to HLA-DC are in progress.

The demonstration of discoordinate expression but similar control by IFN-γ of Ia molecules by human Mφ is important for several reasons. For example, it indicates that accessory cells that express HLA-DR may not express other Ia molecules important in determining their accessory cell function. This consideration is important for studies comparing the relative

accessory cell functions of isolated cell populations. Moreover, it provides a model for investigating the molecular events regulating HLA-DR and HLA-DC gene expression. Although IFN-γ can induce expression of both molecules, other molecular events are obviously important in determining gene expression. The nature of these molecular events is presently under investigation.

Acknowledgments

References

1. Thomas, D. W., V. Yamashita, and E. M. Shevach. 1977. The role of Ia antigens in T-cell activation. *Immunol. Rev.* 35:7–120.

2. Schwartz, R. H., A. Yano, and W. E. Paul. 1978. Interaction between antigen presenting cells and primed T lymphocytes: an assessment of Ir gene expression in the antigen presenting cell. *Immunol. Rev.* 40:153–180.

3. Nagy, Z. A., C. N. Baxevanis, N. Ishii, and J. Klein. 1981. Ia antigens as restriction molecules in Ir-gene controlled T-cell proliferation. *Immunol. Rev.* 60:59–63.

4. Dorf, M. E. 1981. The role of the major histocompatability complex in immunobiology. Garland Publishing, Inc., New York.

5. Goyert, S. M., and J. Silver. Isolation of I-A subregion-like molecules from subhuman primates and man. *Nature (Lond.).* 294:266–268.

6. Goyert, S. M., J. E. Shively, and J. Silver. 1982. Biochemical characterization of a second family of human Ia molecules, HLA-DS, equivalent to murine I-A subregion molecules. *J. Exp. Med.* 156:550–566.

7. Bono, M. R., and J. Strominger. 1982. Direct evidence of homology between human DC-1 antigen and murine I-A molecules. *Nature (Lond.).* 299:836–838.

8. Shackelford, D. A., D. L. Mann, J. J. van Rood, G. B. Ferrara, and J. L. Strominger. 1981. Human B-cell alloantigens DC1, MT1, and LB12 are identical to each other but distinct from the HLA-DR antigen. *Proc. Natl. Acad. Sci. USA.* 78:4566–4570.

9. Corte, G., F. Calabi, G. Damiani, A. Bargellesi, R. Tosi, and R. Sorrentino. 1981. Human Ia molecules carrying DC1 determinants differ in both α and β subunits from Ia molecules carrying DR determinants. *Nature (Lond.).* 292:357–360.

10. Kavathas, P., R. Demars, F. H. Bach, and S. Shaw. 1981. SB: a new HLA-linked human histocompatability gene defined using HLA-mutant lines. *Nature (Lond.).* 293:747–749.

11. Shaw, S., R. Demars, S. F. Schlossman, P. L. Smith, L. A. Lampson, and L. M. Nadler. 1982. Serologic identification of the human secondary B cell antigens: correlations between functions, genetics, and structure. *J. Exp. Med.* 156:731–743.

12. van Leeuwen, A., A. Termijtelen, S. Shaw, and J. J. van Rood. 1982. Recognition of a polymorphic monocyte antigen in HLA. *Nature (Lond.).* 298:565–567.

13. Pawelec, G., S. Shaw, M. Schneider, M. Blaurock, M. Frauer, D. Brackertz, and P. Wernet. 1982. Population studies of HLA-linked SB antigens and their relative importance in primary MLC typing: analysis of HLA-D homozygous typing cells and normal heterozygous populations. *Hum. Immunol.* 5:215–233.

14. Gonwa, T. A., L. J. Picker, H. V. Raff, S. M. Goyert, J. Silver, and J. D. Stobo. 1983. Antigen-presenting capabilities of human monocytes correlate with their expression of HLA-DS, an Ia determinant distinct from HLA-DR. *J. Immunol.* 130:706–711.

15. Peterlin, B. M., T. A. Gonwa, and J. D. Stobo. 1984. Expression of HLA-DR by a human monocyte cell line is under transcriptional control. *J. Mol. Cell. Immunol.* 1:191–200.

16. Steinman, R. M., N. Nogueira, M. D. Witmer, J. D. Tydings, and I. S. Mellman. 1980. Lymphokine enhances the expression and synthesis of Ia antigens on cultured mouse peritoneal macrophages. *J. Exp. Med.* 152:1248–1261.

17. Steeg, P. S., R. N. Moore, and J. J. Oppenheim. 1980. Regulation of murine macrophage Ia-antigen expression by products of activated spleen cells. *J. Exp. Med.* 152:1734–1744.

18. Walker, E. B., L. L. Lanier, and N. L. Warner. 1982. Concomitant induction of the cell surface expression of Ia determinants and accessory cell function by a murine macrophage tumor cell line. *J. Exp. Med.* 155:629–634.

19. Birmingham, J. R., R. W. Chesnut, J. W. Kappler, P. Marrack, R. Kubo, and H. M. Grey. 1982. Antigen presentation to T cell hybridomas by a macrophage cell line: an inducible function. *J. Immunol.* 128:1491–1492.

20. McNicholas, J. M., D. P. King, and P. P. Jones. 1983. Biosynthesis and expression of Ia and H-2 antigens on a macrophage cell line are stimulated by products of activated spleen cells. *J. Immunol.* 130:449–456.

21. Calami, E. G., D. I. Beller, and E. R. Unanue. 1982. Regulation of macrophage populations. IV. Modulation of Ia expression in bone marrow derived macrophages. *J. Immunol.* 128:1692–1694.

22. Steeg, P. A., R. N. Moore, H. M. Johnson, and J. J. Oppenheim. 1982. Regulation of murine macrophage Ia antigen expression by a lymphokine with immune interferon activity. *J. Exp. Med.* 156:1780–1793.

23. King, D. P., and P. P. Jones. 1983. Induction of Ia and H-2 Antigens on a macrophage cell line by immune interferon. *J. Immunol.* 131:315–318.

24. Pober, J. S., and M. A. Gimbrone, Jr. 1982. Expression of Ia-like antigens by human vascular endothelial cells is inducible *in vitro:* demonstration by monoclonal antibody binding and immunoprecipitation. *Proc. Natl. Acad. Sci. USA.* 79:6641–6645.

25. Pober, J. S., M. A. Gimbrone, Jr., R. S. Cotran, C. S. Reiss, S. J. Burakoff, W. Fiers, and K. A. Ault. 1983. Ia expression by vascular endothelium is inducible by activated T cells and by human γ interferon. *J. Exp. Med.* 157:1339–1353.

26. Basham, T. Y., and T. C. Merigan. 1983. Recombinant interferon γ increases HLA-DR synthesis and expression. *J. Immunol.* 130:1492–1494.

27. Dayton, E. T., B. Perussia, and G. Trinchieri. 1983. Correlation

between differentiation, expression of monocyte-specific antigens, and cytotoxic functions in human promyelocytic cell lines treated with leukocyte-conditioned medium. *J. Immunol.* 130:1120–1128.

28. Brodsky, F. M. 1984. A matrix approach to human class II histocompatability antigens: reactions of four monoclonal antibodies with the products of nine haplotypes. *Immunogenetics.* 19:179–194.

29. Raff, H. V., L. J. Picker, and J. D. Stobo. 1980. Macrophage heterogeneity in man. A subpopulation of HLA-DR-bearing macrophages required for antigen-induced T cell activation also contains stimulators for autologous-reactive T cells. *J. Exp. Med.* 152:581–593.

30. Dimitriu-Bona, G. R., S. J. Waters Burmester, and R. J. Winchester. 1983. Human mononuclear phagocytic differentiation antigens. I. Patterns of antigenic expression on the surface of human monocytes and macrophages defined by monoclonal antibodies. *J. Immunol.* 130:145–152.

31. Alpert, S. D., M. E. Jonsen, M. D. Broff, E. Schneeberger, and R. S. Geha. 1981. Macrophage T-cell interaction in man: handling of tetanus toxoid antigen by human monocytes. *J. Clin. Immunol.* 1:21–30.

32. Engleman, E. G., D. J. Charron, C. J. Benike, and G. J. Stewart. 1980. Ia antigens on peripheral blood mononuclear leukocytes in man. I. Expression, biosynthesis, and function of HLA-DR antigens on non-T cells. *J. Exp. Med.* 152(2, Pt. 2):99s–113s.

33. Smith, B. R., and K. Ault. 1981. Increase of surface Ia-like expression on human monocytes independent of antigenic stimuli. *J. Immunol.* 127:2020–2027.

34. Nunez, G., and P. Stastny. 1983. Cytofluorometric analysis of major histocompatability antigens on human monocytes using monoclonal antibodies. *Hum. Immunol.* 6:1–11.

35. Loken, M. R., and L. A. Herzenberg. 1975. Analysis of cell populations with a fluorescence activated cell sorter. *Ann. NY Acad. Sci.* 254:163–171.

36. Muirhead, K. A., T. C. Schmitt, and A. R. Muirhead. 1983. Determination of linear fluorescence intensities from flow cytometric data accumulated with logarithmic amplifiers. *Cytometry.* 3:251–256.

37. Bensussan, A., S. C. Meuer, S. F. Schlossman, and E. L. Reinberg. 1984. Delineation of an immunoregulatory amplifier population recognizing autologous Ia molecules. Analysis with human T cell clones. *J. Exp. Med.* 159:559–576.

38. Rinehart, J. J., R. Vassella, P. Lange, M. E. Kaplan, and B. J. Gormus. 1979. Characterization and comparison of human monocyte- and macrophage-induced tumor cell cytotoxicity. *J. Lab. Clin. Med.* 93:361–369.

39. Mayernik, D. G., A. Ul-Haq, and J. J. Rinehart. 1983. Differentiation-associated alteration in human monocyte-macrophage accessory cell function. *J. Immunol.* 130:2156–2160.

40. George, J. N., L. L. Thai, L. M. McManus, and T. A. Reimann. 1982. Isolation of human platelet membrane microparticles from plasma and serum. *Blood.* 60:834–840.

41. Kratzkin, H., C. Y. Yang, H. Gotz, E. Pauly, S. Kolbel, G. Egert, F. P. Thinnes, P. Wernet, P. Altevogt, and N. Hilschmann. 1981. Primarstruktur menschlicher Histokompatibilitatsantigene der Kasse II. *Hoppe-Seylers Z. Physiol. Chem.* 362:1665–1669.

42. Long, E. O., C. T. Wake, J. Gorski, and B. Mach. 1983. Complete sequence of an HLA-DR β chain deduced from a cDNA clone and identification of multiple non-allelic DR β chain genes. *EMBO (Eur. Mol. Biol. Organ.) J.* 2:389–394.

43. Auffray, C., A. Ben-Nun, M. Roux-Dosseto, R. N. Germain, J. G. Seidman, and J. L. Strominger. 1983. Polymorphism and complexity of the human DC and murine I-A α chain genes. *EMBO (Eur. Mol. Biol. Organ.) J.* 2:121–124.

44. Karr, R. W., C. C. Kannapell, J. A. Stein, T. C. Fuller, R. J. Duquesnoy, G. E. Rodey, D. L. Mann, H. M. Gebel, and B. D. Schwartz. 1982. Demonstration of a third structurally distinct human Ia beta chain by two-dimensional electrophoresis. *J. Exp. Med.* 156:652–657.

45. Cowing, C., B. D. Schwartz, and H. B. Dickler. 1978. Macrophage Ia antigens. I. Macrophage populations differ in their expression of Ia antigens. *J. Immunol.* 120:378–384.

46. Cowing, C., S. H. Pincus, D. H. Sachs, and H. B. Dickler. 1978. A subpopulation of adherent accessory cells bearing both I-A and I-E or C subregions is required for antigen-specific murine T lymphocyte proliferation. *J. Immunol.* 121:1680–1686.

47. Nepom, J. T., B. Benaceraff, and R. N. Germain. 1981. Analysis of Ir gene function using monoclonal antibodies: independent regulation of GAT and GLPhe T cell response by I-A and I-E subregion products on a single accessory cell population. *J. Immunol.* 127:31–34.

48. Huber, B. T., and L. J. Rosenwasser. 1982. Role of Ia.W39 in the interaction of antigen-presenting cells with T and B lymphocytes. *Eur. J. Immunol.* 12:37–43.

49. Wang, C. Y., A. Al-Katib, C. L. Lane, B. Kozinei, and S. M. Fu. 1983. Induction of HLA-DC/DS (Leu 10) antigen expression by human precursor B cell lines. *J. Exp. Med.* 158:1757–1762.

50. Sztein, M. B., P. S. Steeg, H. M. Johnson, and J. J. Oppenheim. 1984. Regulation of human peripheral blood monocyte DR antigen expression in vitro by lymphokines and recombinant interferons. *J. Clin. Invest.* 73:556–565.

51. Rosa, F., D. Hatat, A. Abadie, D. Wallach, M. Revel, and M. Fellous. 1983. Differential regulation of HLA-DR mRNAs and cell surface antigens by interferon. *EMBO (Eur. Mol. Biol. Organ.) J.* 2:1585–1589.

52. Bar-Shavit, Z., S. L. Teitelbaum, P. Reitsma, A. Hall, L. E. Pegg, J. Trial, and A. J. Kahn. 1983. Induction of monocyte differentiation and bone resorption by 1,25 dihydroxy vitamin D3. *Proc. Natl. Acad. Sci. USA.* 80:5907–5911.

53. Reitsma, P. H., P. G. Rothberg, S. M. Astrin, J. Trial, Z. Bar-Shavit, A. Hall, S. L. Teitelbaum, and A. J. Kahn. 1983. Regulation of *myc* gene expression in HL-60 leukemia cells by a vitamin D metabolite. *Nature (Lond.).* 306:492–493.